Rezension:

I'm not interested in football discount coupons for strattera Until the high court struck down some of Myriads BRCA patents in June, the company held a monopoly over the tests, though it has said its remaining patents should continue to bar competitors. BRCA screenings, along with a recommended supplemental test, represented $519.41 million in sales for Myriad in its most recent fiscal year, or 85% of the companys total revenue.

Bewertung: